The University of Southampton
University of Southampton Institutional Repository

Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation

Record type: Article

Background: Topotecan is a relatively new drug for use as a second-line treatment in patients with relapsed small cell lung cancer (SCLC). We performed a systematic review and economic evaluation of topotecan, and consider it here in relation to the NICE end of life criteria.

Methods: Seventeen bibliographic databases (including Cochrane library, Medline and Embase) were searched from 1990 to February 2009, and experts and manufacturers were consulted, to identify relevant randomised controlled trials (RCTs) which were selected according to prospectively defined criteria. An economic evaluation was undertaken to assess cost effectiveness compared with best supportive care (BSC) in the UK.

Results: Five RCTs were included. The clinical evidence indicates a statistically significant benefit of oral topotecan plus BSC compared to BSC alone for overall survival. Intravenous topotecan was similar in efficacy to both oral topotecan and CAV (cyclophosphamide, doxorubicin and vincristine). In the survival model, oral topotecan plus BSC was associated with an average gain in life expectancy of approximately 4months, resulting in a gain of 0.183 quality-adjusted life years (QALYs). At an incremental cost of approximately pound6200 the incremental cost effectiveness ratio (ICER) is pound33,851 per QALY gained.

Conclusions: Compared with BSC alone, oral topotecan for patients with relapsed SCLC was associated with improved health outcomes but at increased cost. The ICER is at the upper extreme of the range conventionally regarded as cost effective from an NHS decision making perspective. However, this treatment may fall under supplementary guidance for life extending, end of life treatments.

Full text not available from this repository.

Citation

Hartwell, Debbie, Jones, Jeremy, Loveman, Emma, Harris, Petra, Clegg, Andrew J. and Bird, Alex (2010) Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation Cancer Treatment Reviews, 37, (3), pp. 242-249. (doi:10.1016/j.ctrv.2010.07.005). (PMID:20709456).

More information

Published date: August 2010

Identifiers

Local EPrints ID: 168281
URI: http://eprints.soton.ac.uk/id/eprint/168281
ISSN: 0305-7372
PURE UUID: 41327f58-650d-4cf1-9739-5fd5a4b320f1

Catalogue record

Date deposited: 26 Nov 2010 12:43
Last modified: 18 Jul 2017 12:23

Export record

Altmetrics

Contributors

Author: Debbie Hartwell
Author: Jeremy Jones
Author: Emma Loveman
Author: Petra Harris
Author: Andrew J. Clegg
Author: Alex Bird

University divisions


Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×